Evidence map›Paper›PMID 38145424›Full record

ArticleMolecular diversity2024

Design, synthesis, and pharmacological evaluation of indazole carboxamides of N-substituted pyrrole derivatives as soybean lipoxygenase inhibitors.

Vasiliki Lavrentaki, Antonios Kousaxidis, Panagiotis Theodosis-Nobelos, Georgios Papagiouvannis, Konstantinos Koutsopoulos, Ioannis Nicolaou

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vasiliki Lavrentaki *Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Antonios Kousaxidis *Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
Panagiotis Theodosis-NobelosDepartment of Pharmacy, School of Health Sciences, Frederick University, 1036, Nicosia, Cyprus.
Georgios PapagiouvannisDepartment of Pharmacy, School of Health Sciences, Frederick University, 1036, Nicosia, Cyprus.
Konstantinos KoutsopoulosCentral Cytotoxic Preparation Unit, 251 General Air Force Hospital, Athens, Greece.
Ioannis NicolaouDepartment of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece. inikolao@pharm.auth.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this paper, we attempted to develop a novel class of compounds against lipoxygenase, a key enzyme in the biosynthesis of leukotrienes implicated in a series of inflammatory diseases. Given the absence of appropriate human 5-lipoxygenase crystallographic data, solved soybean lipoxygenase-1 and -3 structures were used as a template to generate an accurate pharmacophore model which was further used for virtual screening purposes. Eight compounds (1-8) have been derived from the in-house library consisting of N-substituted pyrroles conjugated with 5- or 6-indazole moieties through a carboxamide linker. This study led to the discovery of hit molecule 8 bearing a naphthyl group with the IC

Indexed as

Drug DesignEdemaGlycine maxIndazolesLipoxygenaseLipoxygenase InhibitorsPyrrolesAnimalsAnti-Inflammatory AgentsCarrageenanMaleModels, MolecularMolecular Docking SimulationStructure-Activity RelationshipAnti-Inflammatory AgentsCarrageenanIndazolesLipoxygenaseLipoxygenase InhibitorsPyrrolesInflammationMolecular dockingPharmacophore modelPyrrole-indazole derivativesSoybean lipoxygenaseVirtual screening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.